Background: Tremendous efforts have been made to establish the concept of vascular restoration
| I N TR ODU C TI ON
Bioresorbable scaffolds have been heralded as the latest revolution in the field of percutaneous coronary intervention (PCI) [1, 2] . Unlike permanent metallic drug-eluting stents (DES), bioresorbable scaffolds are designed to provide temporary structural integrity before being resorbed completely within the vessel. The transient presence of the scaffold offers a potential solution to the drawbacks of metallic DES; these drawbacks include hypersensitivity reactions, endothelial dysfunction, late stent thrombosis (ST), and preclusion of future surgical revascularization at the same lesion [3] [4] [5] . With rapid technological advancement, cardiac multislice computed tomography (MSCT) angiography is currently considered to be an established technique for noninvasive evaluation of the coronary lumen and coronary plaques [6] .
However, MSCT assessment of a previously stented coronary artery is limited because of metal artifacts. Because of its radiolucent, polylactide backbone, the NeoVas scaffold does not affect computed tomography image interpretation, and MSCT can be used to assess changes in the lumen and vessels after its implantation.
The angiographic, intravascular ultrasonography (IVUS), and optical coherence tomography (OCT) outcomes of this study were previously reported at the 6 months follow-up [7] . However, the clinical outcomes of the NeoVas scaffold for patients with single de novo lesions and plaque and lumen evolution at the 1 year follow-up remain to be investigated to confirm the safety and effectiveness of the technology. We herein report the clinical outcomes and luminal measurements by MSCT in the original cohort of patients treated with NeoVas scaffolds in the first-in-man trial at 12 months.
| M E TH ODS

| Study design and patient population
The design of this study was previously reported [7] . Briefly, in this single-arm, prospective, open label study with safety and imaging endpoints, 31 patients were enrolled at two participating sites between July and September 2014. Patients were older than 18 years of age with a diagnosis of stable, unstable, or silent ischemia. All treated lesions were single de novo in a native coronary artery lesion. Lesions were required to have a visually estimated stenosis of 70% and be <100% in diameter, a reference vessel diameter (RVD) between 2.75 and 3.75 mm, length of 20 mm, and be suitable for a single stent only. The major exclusion criteria included the following: acute myocardial infarction within 1 month, chronic total occlusion lesions, ostial lesions, left main coronary artery disease, bifurcation lesions involving a side branch 2.0 mm in diameter, in-stent restenosis lesions, heavily calcified lesions, lesions with excessive tortuosity or extreme lesion angulation, New York Heart Association grade 3, and left ventricular ejection fraction 40%. The intravascular imaging examinations were performed at baseline and 6 months and 2 years of follow-up.
The study protocol was reviewed and approved by the institutional ethics committees of the two participating sites. All participants provided written informed consent, and the study was conducted in accordance with the principles of Helsinki and Good Clinical Practice guidelines. The study is registered with ClinicalTrials.gov identifier: NCT02195414.
| Medication treatment
All patients received treatment with aspirin (300 mg at least 24 h before the procedure and 100 mg daily thereafter) and clopidogrel (loading dose of 300 mg at least 6 h before the procedure, followed by 75 mg daily for 12 months). During the procedure, an anticoagulant (e.g., heparin) was administered as per the protocol (100 units/kg, ACT > 250 s). Glycoprotein IIb/IIIa inhibitors were left to the operator's discretion. After the intervention, all patients were treated with 100 mg/day aspirin indefinitely for life. Clopidogrel (75 mg/day) was continued for at least 1 year, along with other medications according to the judgement of the patient's physician.
| Study device
The study device, the NeoVas scaffold (Lepu Medical, Beijing, China), is a balloon expandable, bioresorbable scaffold that consists of a back- The scaffold sizes studied in the trial were 3.0 and 3.5 mm in diameter and 12, 15, 18, and 24 mm in length.
| Clinical outcomes
In this study, we report all cause death, TLF, and its components and scaffold thrombosis using the Academic Research Consortium definition at 1 year. A diagnosis of clinically indicated TLR implies revascularization at the target lesion, irrespective of the time window for angiographic control, associated with (1) a positive functional ischemia study; (2) ischemic symptoms and angiographic minimal lumen diameter stenosis 50% by core laboratory quantitative coronary angiography (QCA); or (3) revascularization of a target lesion with a diameter stenosis 70% by core laboratory QCA without either ischemic symptoms or a positive functional study. MI was defined as the development of new Q waves in association with a rise in creatine kinase (CK) 2 times the upper limit of normal; non-Q-wave MI was defined as a CK elevation 2 times the upper limit of normal together with an elevation in CK-myocardial band levels. An independent clinical events committee adjudicated all events.
| MSCT angiography and data analysis
Standard acquisition techniques were used and included beta-blockers in patients with a fast heart rate, tube settings depending on the patient size (80-140 kV), and axial scan protocols for patients with lower heart rates to reduce radiation doses, all of which were at the discretion of the individual sites. Images were reconstructed using thin slices (0.5-0.67 mm) and medium smooth reconstruction filters, including 1 or several phases depending on the scan protocol. All data were stored on a DVD for core laboratory evaluation.
The CT data were analyzed on a dedicated workstation using a validated cardiovascular analysis package. Semiautomatically, a center lumen line was created through the treated coronary branch, after which cross-sectional views of the vessel were reconstructed at 1 mm longitudinal steps, including 5 mm proximal and distal to the device, using the platinum indicators as landmarks. Automatic segmentation of the vessel lumen, with manual correction, was performed to measure the lumen area. The outer vessel borders were manually traced to approximately the total vessel size using fixed window display settings: level, 750 Hounsfield units; width, 250 Hounsfield units. The mean, minimal, and maximal lumen areas within the treated lesion were determined for each slice. The reference vessel lumen area was calculated as the average of the mean proximal and mean distal vessel areas. Lumen area stenosis was calculated as the reference minus the minimal lumen area as a percentage of the reference lumen area. In case of an ostial lesion or overlapping conventional stents, the reference lumen diameter was based on measurements of the opposite end only. Significant area stenosis was defined as 75%, which approximates a 50% diameter stenosis. Each cross-section was qualitatively assessed for the presence of a noncalcified plaque, calcified plaque, and mixed plaque [8] [9] [10] . The percentage of cross-sections of each plaque type was calculated as the number of cross-sections, with the plaque type divided by the total number of cross-sections analyzed in the scaffolded segment.
| Statistical analysis
Data from all patients were analyzed according to the full analysis set principle. Continuous variables are presented as the median and interquartile, and categorical data are presented as the counts and percentages. All statistical analyses were performed with SPSS software, version 21.0 (IBM corp., Armonk, NY, USA).
| R E SU LTS
| Baseline patient characteristics
Out of 31 patients enrolled in the NeoVas trial, 29 patients received MSCT angiography at the 1 year follow-up. The mean age of these patients was 59.3 6 9.0 years, and 75.9% were male (Table 1) . Hypertension was observed in 48.3% of patients, diabetes mellitus in 24.1%, hypercholesterolemia in 37.9%, and current smoker in 41.4%. The baseline lesion and procedural characteristics of these 29 patients are shown in Table 2 . The mean reference vessel diameter and lesion length were 3.37 6 0.29 mm and 14.9 6 3.6 mm, respectively. The scaffold diameter and length were 3.3 6 0.2 mm and 19.0 6 3.4 mm, respectively. 
| Quantitative MSCT results at 12 months
| Clinical follow-up
Clinical follow-up was completed in all 31 patients at 1 and 12 months.
There was no TLF or any other adverse events at 30 days of follow-up.
Up to 12 months, there was only 1 (3.2%) TLF, attributed to 1 patient who suffered ischemia-driven TLR at 181 days postprocedure (Table   4 ). No cardiac deaths or scaffold thrombosis were observed at the 1-year follow-up.
| D ISC USSION
This prospective, two-center, first-in-man trial has demonstrated for the first time that (1) Coronary atherosclerosis is a continuous disease process and necessitates preventive measures and intensive pharmacological treatment. Indeed, after bioresorption of the polymer, the vessel and lumen are able to change dynamically in response to physiological stimuli, the biological environment, and pharmacological treatment as a result of the absence of permanent metal endoluminal prosthesis [15] . This emphasizes the importance of treating the underlying atherosclerotic process after bioresorbable scaffold implantation. It should be underscored that in the absence of a metal structure, restenosis after scaffolding can be treated with another scaffold without any of the complexities of treating classic in-stent restenosis within a metal stent.
In the near future, scaffolding, in theory, could be applied after appropriate preparation of the stenotic lesion using classic tools of the interventional cardiologist, such as rotablators, cutting balloons, laser, highpressure balloons, and others.
| LI M I TA TI ON S
The limitations of this study include the small cohort of patients, follow-up duration of 12 months, and lack of randomization typical for an exploratory first-in-man study; however, for such a novel technology, choosing an appropriate control arm remains challenging.
| CON CL U S I ONS
This first-in-man study was designed to assess the feasibility of the deployment of the NeoVas bioresorbable scaffold in single, de novo, native coronary artery lesions while providing an understanding of the device with regard to the scaffolding properties, unique features, and vascular response. There was only 1 clinical adverse event through 12 months that was directly attributable to the NeoVas coronary scaffold.
At 12 months, MSCT demonstrated the maintenance of the vessel dimensions. This information provides the necessary impetus to test the next iteration of this novel device in a larger cohort of patients. 
